Vera Therapeutics, Inc.
VERAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. Valued at $2.76B, VERA is a mid-cap name in its sector. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Market Cap
$2.76B
Beta
0.92
P/E (TTM)
—
P/E (Fwd)
-9.98
EPS (TTM)
$-5.44
EPS (Fwd)
$-3.86
ROE
-71.3%
ROA
-38.9%
Cash
$596.8M
Total Debt
$76.9M
Free CF
-$179.4M
52W Change
67.0%
Annual Financials
Cash vs Debt
With $596.8M in cash and $76.9M in debt, VERA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$179.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -71.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, VERA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vera Therapeutics, Inc. and its sector.